Trexquant Investment LP Decreased Its Position in Cdk Global (CDK) by $343,728 as Stock Value Declined; Davidson Kempner Capital Management LP Stake in Charles Riv Labs Intl (CRL) Has Upped as Market Valuation Rose

February 15, 2018 - By reb123z

Thomas Lenox Kempner increased its stake in Charles Riv Labs Intl Inc (CRL) by 62.5% based on its latest 2017Q3 regulatory filing with the SEC. Davidson Kempner Capital Management Lp bought 62,500 shares as the company’s stock rose 1.24% with the market. The hedge fund run by Thomas Lenox Kempner held 162,500 shares of the health care company at the end of 2017Q3, valued at $17.55M, up from 100,000 at the end of the previous reported quarter. Davidson Kempner Capital Management Lp who had been investing in Charles Riv Labs Intl Inc for a number of months, seems to be bullish on the $5.15 billion market cap company. The stock decreased 1.38% or $1.52 during the last trading session, reaching $108.79. About 192,348 shares traded. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 7.06% since February 15, 2017 and is uptrending. It has underperformed by 9.64% the S&P500.

Trexquant Investment Lp decreased its stake in Cdk Global Inc (CDK) by 47.86% based on its latest 2017Q3 regulatory filing with the SEC. Trexquant Investment Lp sold 5,456 shares as the company’s stock declined 6.12% while stock markets rallied. The institutional investor held 5,944 shares of the miscellaneous company at the end of 2017Q3, valued at $375,000, down from 11,400 at the end of the previous reported quarter. Trexquant Investment Lp who had been investing in Cdk Global Inc for a number of months, seems to be less bullish one the $9.36B market cap company. The stock decreased 2.86% or $2.05 during the last trading session, reaching $69.57. About 772,129 shares traded. CDK Global, Inc. (NASDAQ:CDK) has risen 18.92% since February 15, 2017 and is uptrending. It has outperformed by 2.22% the S&P500.




Trexquant Investment Lp, which manages about $105.00 million and $396.96M US Long portfolio, upped its stake in Quidel Corp (NASDAQ:QDEL) by 10,283 shares to 22,883 shares, valued at $1.00 million in 2017Q3, according to the filing. It also increased its holding in Immunogen Inc (NASDAQ:IMGN) by 71,936 shares in the quarter, for a total of 104,633 shares, and has risen its stake in Dst Sys Inc Del (NYSE:DST).

Among 8 analysts covering CDK Global (NASDAQ:CDK), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. CDK Global had 15 analyst reports since August 14, 2015 according to SRatingsIntel. As per Wednesday, June 21, the company rating was upgraded by Wells Fargo. On Monday, July 10 the stock rating was upgraded by Evercore to “Outperform”. The stock has “Neutral” rating by JP Morgan on Wednesday, April 6. The firm has “Buy” rating given on Wednesday, January 31 by Wells Fargo. As per Friday, February 3, the company rating was upgraded by Morgan Stanley. The firm has “Underweight” rating by JP Morgan given on Tuesday, December 15. The rating was downgraded by Morgan Stanley to “Underweight” on Tuesday, January 19. The rating was upgraded by Barrington Research on Thursday, February 4 to “Outperform”. Barrington Research downgraded the stock to “Market Perform” rating in Wednesday, January 17 report. JP Morgan maintained the stock with “Underweight” rating in Friday, August 14 report.

Since August 14, 2017, it had 0 buys, and 4 insider sales for $4.07 million activity. JOHST DAVID P also sold $2.72 million worth of Charles River Laboratories International, Inc. (NYSE:CRL) on Thursday, October 5. On Thursday, October 5 Molho Davide sold $678,150 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 6,165 shares. $382,229 worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by FOSTER JAMES C. $171,228 worth of Charles River Laboratories International, Inc. (NYSE:CRL) shares were sold by Smith David Ross.

Investors sentiment increased to 1.46 in 2017 Q3. Its up 0.09, from 1.37 in 2017Q2. It is positive, as 18 investors sold CRL shares while 92 reduced holdings. 55 funds opened positions while 106 raised stakes. 44.95 million shares or 0.15% less from 45.02 million shares in 2017Q2 were reported. 6,549 were reported by Symphony Asset Mngmt Limited Liability Com. Jefferies Group Limited Liability Company invested in 15,156 shares. Gsa Capital Prtn Ltd Liability Partnership invested in 23,184 shares. United Automobile Association has 16,900 shares for 0.01% of their portfolio. New York-based Loews has invested 0% in Charles River Laboratories International, Inc. (NYSE:CRL). Tekla Capital Management Limited Com holds 0.49% or 127,100 shares in its portfolio. Bluemountain Ltd Liability Com accumulated 12,863 shares. Apg Asset Mgmt Nv holds 102,100 shares. Connecticut-based Aqr Mgmt Limited Liability Company has invested 0.19% in Charles River Laboratories International, Inc. (NYSE:CRL). State Of Alaska Department Of Revenue holds 0.02% or 3,600 shares in its portfolio. Los Angeles Mngmt & Equity, California-based fund reported 13,342 shares. Lpl Fincl Lc has invested 0% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). Cantab Capital Ptnrs Llp holds 0.22% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL) for 14,316 shares. Beck Capital Mngmt Limited Liability Corp holds 4,215 shares or 0.22% of its portfolio. Schwab Charles Investment Mngmt Inc invested in 0.03% or 282,765 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: